29 Sep BioCurie
Irene Rombel, President, CEO and Co-Founder
Oct. 6 | 2:30pm | FLW Ballroom G
Wilmington, Delaware
(Private)
BioCurie is pioneering mechanistic AI (mAI) to transform cell and gene therapy development and manufacturing. Founded by Dr. Irene Rombel (J&J, Spark Therapeutics) and Professor Richard Braatz (world leader in AI/ML for manufacturing, Director, MIT Center for mRNA Manufacturing), BioCurie has built an intelligent digital twin platform for genomic medicine production. The patented mAI BioCurie™ platform enables biopharma teams to predict, optimize, and control manufacturing from early development through scale-up, tech transfer, and commercial production. By running millions of in silico experiments, the software platform improves product quality, time, and cost. BioCurie has been invited to educate HHS on AI-driven CGT production and has won global innovation awards, including Cure Xchange Health AI for Good, the King Faisal-Davos Healthcare Innovation AI Challenge, and an ARPA-H award for Scalable AI-Driven Solutions. BioCurie empowers developers and manufacturers of all sizes to bring curative genomic medicines to patients faster and affordably.